Physician profile
Eva Case
NPI 1750820841
$2,014.18
in general payments reported to CMS, 2019-2025
20 companies · $1,029 in 2025
The $1,029 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.71 · 2022: $175 · 2023: $207 · 2024: $548 · 2025: $1,029.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,784.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $655.29 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $455.14 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $175.00 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Vanda Pharmaceuticals INC. | $137.42 | 2025 | Fanapt |
| Lilly USA, LLC | $105.45 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $57.37 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $55.99 | 2024-2025 | Rexulti |
| Lundbeck LLC | $49.34 | 2025 | Rexulti |
| Exact Sciences Corporation | $49.07 | 2023-2025 | Cologuard Collection Kit |
| Axsome Therapeutics, INC. | $35.57 | 2024-2025 | Auvelity |
| Novo Nordisk INC | $32.90 | 2021-2024 | |
| Therapeuticsmd, INC. | $30.22 | 2022 | |
| Dexcom, INC. | $28.58 | 2022-2024 | Dexcom G6 Transmitter |
| Myovant Sciences INC. | $27.75 | 2021-2022 | |
| Allergan, INC. | $24.40 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $22.45 | 2024 | Voquezna |
| Sumitomo Pharma America, INC. | $21.12 | 2025 | Gemtesa |
| Pfizer INC. | $18.95 | 2025 | |
| Antares Pharma, INC. | $16.35 | 2024 | Xyosted |
| Viatris Specialty LLC | $15.82 | 2025 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eva Case listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.